Acumen Pharmaceuticals (NASDAQ: ABOS) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, and will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Participants must register in advance to receive dial-in details and PIN, while the webcast will be accessible online, with an archived version available for at least 30 days in the Investors section of Acumen’s website. The company is a clinical-stage biopharmaceutical developer of sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers in Alzheimer’s disease, now in an ongoing Phase 2 trial ALTITUDE-AD, with additional work on subcutaneous and enhanced brain delivery formulations.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Recent insider activity was classified as Net Selling across 4 transactions, adding governance conte...
Analysis
Recent insider activity was classified as Net Selling across 4 transactions, adding governance context to this scheduling notice. The active S-3 is a resale registration, not company financing; low short positioning adds a separate risk context.
Key Figures
Financial results date:August 12, 2026Conference call time:8:00 a.m. ETWebcast archive:At least 30 days+3 more
"therapeutics that target toxic soluble amyloid beta oligomers"
Small, soluble clumps of a brain protein called amyloid beta that can interfere with nerve cell function and are suspected to drive memory loss in neurodegenerative disease. Investors watch them because drugs that reduce or neutralize these oligomers are a major focus of research, and convincing evidence that a treatment affects them can sway clinical trial success, regulatory decisions and a company’s valuation — like finding the right lock-and-key to stop engine damage.
humanized monoclonal antibodymedical
"a humanized monoclonal antibody that selectively targets synaptotoxic AβOs"
A humanized monoclonal antibody is a laboratory-made protein designed to target a specific molecule in the body, where the antibody’s parts derived from a nonhuman source have been modified to more closely resemble human antibodies. Investors watch these because the “humanized” design can reduce immune reactions, improve how long the drug stays in the body and affect clinical success, manufacturing complexity, regulatory review and potential market value—like redesigning a tool to fit standard parts.
blood-brain barrier-penetrating technologymedical
"a transferrin-receptor-targeting blood-brain barrier-penetrating technology"
Technology designed to help therapeutic or diagnostic agents cross the blood-brain barrier, the brain’s natural “security gate” that blocks many molecules from entering from the bloodstream. Methods include chemical modification, carrier systems, nanoparticles, or specialized delivery techniques that allow drugs to reach brain tissue. This matters to investors because it can expand the market for treatments of neurological conditions and change the scientific, regulatory and clinical risks tied to drug development.
subcutaneous formulationmedical
"investigating a subcutaneous formulation of sabirnetug"
A subcutaneous formulation is a medicine prepared to be injected just under the skin, where it is absorbed into the body more slowly than an intravenous dose. For investors, this matters because subcutaneous versions often allow treatment at home or in a clinic instead of a hospital, improving patient convenience, lowering administration costs, expanding market access, and potentially increasing sales and competitive advantage compared with treatments that require more complex or frequent medical visits.
NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter financial results on Wednesday, Aug. 12, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets synaptotoxic AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery™ (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
When will Acumen Pharmaceuticals (NASDAQ: ABOS) report Q2 2026 financial results?
Acumen Pharmaceuticals will report its second quarter 2026 financial results on Wednesday, August 12, 2026. According to the company, the announcement will be accompanied by a business and financial update via conference call and live webcast that same morning.
What time is Acumen Pharmaceuticals’ Q2 2026 earnings conference call for ABOS shareholders?
The Acumen Pharmaceuticals second quarter 2026 conference call starts at 8:00 a.m. Eastern Time. According to the company, the call will include a business and financial update and will be accessible via pre-registered dial-in details and a simultaneous live audio webcast.
How can investors access the Acumen Pharmaceuticals (ABOS) Q2 2026 earnings webcast?
Investors can access the Q2 2026 Acumen Pharmaceuticals webcast through an online audio link provided by the company. According to Acumen, a replay will remain available for at least 30 days in the Investors section of its website, acumenpharm.com.
Do investors need to register to join Acumen Pharmaceuticals’ August 12, 2026 ABOS earnings call?
Yes, investors must register in advance to join Acumen Pharmaceuticals’ August 12, 2026 earnings call. According to the company, registration provides the dial-in numbers and PIN, and participants are advised to complete registration at least one day before the event.
What Alzheimer’s drug candidate will Acumen Pharmaceuticals (ABOS) discuss around its Q2 2026 update?
Acumen Pharmaceuticals is advancing sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers. According to the company, sabirnetug is in the ongoing Phase 2 ALTITUDE-AD trial in early symptomatic Alzheimer’s disease following positive Phase 1 INTERCEPT-AD results.
What clinical programs is Acumen Pharmaceuticals (ABOS) running as of August 2026?
Acumen is running the Phase 2 ALTITUDE-AD trial of sabirnetug in early symptomatic Alzheimer’s disease. According to the company, it is also studying a subcutaneous formulation with Halozyme’s ENHANZE technology and collaborating with JCR Pharmaceuticals on Enhanced Brain Delivery therapy.
Where can I find the archived replay of Acumen Pharmaceuticals’ Q2 2026 ABOS webcast?
The archived replay of Acumen Pharmaceuticals’ Q2 2026 webcast will be available in the Investors section of acumenpharm.com. According to the company, this archived version will be accessible for at least 30 days after the live event.
